Effect of a Novel NOP Receptor Agonist (SCH 225288) on Guinea Pig Irritant-Evoked, Feline Mechanically Induced and Canine Infectious Tracheobronchitis Cough
Background: Previous studies have demonstrated that nociceptin/orphanin FQ (N/OFQ), the endogenous peptide ligand for the G-protein-coupled NOP receptor, inhibits cough in experimental models. SCH 225288 is a nonpeptide, orally active NOP agonist that may provide the foundation for the development o...
Gespeichert in:
Veröffentlicht in: | Pharmacology 2009-01, Vol.84 (3), p.153-161 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 161 |
---|---|
container_issue | 3 |
container_start_page | 153 |
container_title | Pharmacology |
container_volume | 84 |
creator | McLeod, Robbie L. Tulshian, Deen B. Ho, Ginny D. Fernandez, Xiomara Bolser, Donald C. Parra, Leonard E. Zimmer, Jennifer C. Erickson, Christine H. Fawzi, Ahmad B. Jayappa, Huchappa Lehr, Craig Erskine, Jason Smith-Torhan, April Zhang, Hongtao Hey, John A. |
description | Background: Previous studies have demonstrated that nociceptin/orphanin FQ (N/OFQ), the endogenous peptide ligand for the G-protein-coupled NOP receptor, inhibits cough in experimental models. SCH 225288 is a nonpeptide, orally active NOP agonist that may provide the foundation for the development of novel treatments for cough. Methods: First we characterized the selectivity of SCH 225288 in human receptor binding assays. Afterwards, the antitussive activity of SCH 225288 was studied in three mechanistically distinct cough models. Specifically, we observed the cough-suppressant effect of SCH 225288 in a guinea pig capsaicin irritant-evoked cough model, a feline mechanically induced cough model and finally in a canine Bordetella bronchiseptica disease model. Results: SCH 225288 selectively binds human NOP receptor (K i = 0.38 ± 0.02 nmol/l) over classical opioid receptors (COR). In a guinea pig capsaicin cough model, SCH 225288 (0.1–1 mg/kg) suppressed cough at 2, 4, and 6 h after oral administration. The antitussive effect of SCH 225288 (3.0 mg/kg, p.o.) was blocked by the NOP antagonist J113397 (12 mg/kg, i.p.) but not by the classical opioid receptor (COR) antagonist, naltrexone (3.0 mg/kg, i.p.). In the anesthetized cat, we evaluated the effects of SCH 225288 given either intravenously or via the intravertebral artery against the increases in cough number and respiratory expiratory and inspiratory muscle (rectus abdominis and parasternal) electromyographic (EMG) activities due to perturbations of the intrathoracic trachea. SCH 225288 (0.03–3.0 mg/kg, i.v.) inhibited both cough number and abdominal EMG amplitudes. Similarly, SCH 225288 (0.001–0.3 mg/kg) administered intra-arterially also diminished cough number and abdominal EMG amplitudes. No significant effect of the drug was noted on parasternal EMG activity. Finally, we studied the antitussive actions of SCH 225288 (1.0 mg/kg) in a canine B. bronchiseptica disease model. In this model, dogs were challenged intranasally with B. bronchiseptica. Comparisons were made between a vehicle group, an SCH 225288 (1.0 mg/kg, p.o., q.d.) and a butorphanol (0.6 mg/kg, p.o., b.i.d.) group on the mean change in cough scores from baseline values and days 6–9 after B. bronchiseptica challenge. SCH 225288 (1.0 mg/kg, p.o., q.d.) displayed a positive antitussive tendency (p = 0.06) to inhibit B. bronchiseptica cough whereas butorphanol (0.6 mg/kg, p.o., b.i.d.) was devoid of antitussive activity. Conclusions: Taken tog |
doi_str_mv | 10.1159/000235601 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000235601</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2770126921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-f43f222e4b2d0baabd84397ab0775c703b369ef5121dc73c861459dbacdc3ab03</originalsourceid><addsrcrecordid>eNpt0ctO3DAUBmCroioD7YI9QkfqpkiE-pLEyXIUDcxIXEYtXUeOLzOGYA92gsS78LAYzQg2XR3J59P_Sz4IHRF8TkhR_8YYU1aUmHxBE5JTlmFG2B6a4DQzjgndRwcx3idWUl59Q_ukLuuyoGSCXmfGaDmANyDgxj_rHm5ul_BHS70ZfIDpyjsbB_j1t5kDpQWtqlPwDi5H67SApV3BIgQ7CDdks2f_oNUZXOg-LeFay7VwVoq-f4GFU6PUCoRT0KTXtF-492brxwh3Qci19l3wTq7tYCM0flytv6OvRvRR_9jNQ_TvYnbXzLOr28tFM73KJCvJkJmcGUqpzjuqcCdEp6qc1Vx0mPNCcsw6VtbaFIQSJTmTVUnyoladkEqypNgh-rnN3QT_NOo4tPd-DC5VtgSXNeM5r_OkTrdKBh9j0KbdBPsowktC7fsd2o87JHuySxy7R60-5e7jPysfRFjp8AGW8-k2ot0ok9Txf9Wu5Q1x75YQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1069374794</pqid></control><display><type>article</type><title>Effect of a Novel NOP Receptor Agonist (SCH 225288) on Guinea Pig Irritant-Evoked, Feline Mechanically Induced and Canine Infectious Tracheobronchitis Cough</title><source>Karger Journals</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>McLeod, Robbie L. ; Tulshian, Deen B. ; Ho, Ginny D. ; Fernandez, Xiomara ; Bolser, Donald C. ; Parra, Leonard E. ; Zimmer, Jennifer C. ; Erickson, Christine H. ; Fawzi, Ahmad B. ; Jayappa, Huchappa ; Lehr, Craig ; Erskine, Jason ; Smith-Torhan, April ; Zhang, Hongtao ; Hey, John A.</creator><creatorcontrib>McLeod, Robbie L. ; Tulshian, Deen B. ; Ho, Ginny D. ; Fernandez, Xiomara ; Bolser, Donald C. ; Parra, Leonard E. ; Zimmer, Jennifer C. ; Erickson, Christine H. ; Fawzi, Ahmad B. ; Jayappa, Huchappa ; Lehr, Craig ; Erskine, Jason ; Smith-Torhan, April ; Zhang, Hongtao ; Hey, John A.</creatorcontrib><description>Background: Previous studies have demonstrated that nociceptin/orphanin FQ (N/OFQ), the endogenous peptide ligand for the G-protein-coupled NOP receptor, inhibits cough in experimental models. SCH 225288 is a nonpeptide, orally active NOP agonist that may provide the foundation for the development of novel treatments for cough. Methods: First we characterized the selectivity of SCH 225288 in human receptor binding assays. Afterwards, the antitussive activity of SCH 225288 was studied in three mechanistically distinct cough models. Specifically, we observed the cough-suppressant effect of SCH 225288 in a guinea pig capsaicin irritant-evoked cough model, a feline mechanically induced cough model and finally in a canine Bordetella bronchiseptica disease model. Results: SCH 225288 selectively binds human NOP receptor (K i = 0.38 ± 0.02 nmol/l) over classical opioid receptors (COR). In a guinea pig capsaicin cough model, SCH 225288 (0.1–1 mg/kg) suppressed cough at 2, 4, and 6 h after oral administration. The antitussive effect of SCH 225288 (3.0 mg/kg, p.o.) was blocked by the NOP antagonist J113397 (12 mg/kg, i.p.) but not by the classical opioid receptor (COR) antagonist, naltrexone (3.0 mg/kg, i.p.). In the anesthetized cat, we evaluated the effects of SCH 225288 given either intravenously or via the intravertebral artery against the increases in cough number and respiratory expiratory and inspiratory muscle (rectus abdominis and parasternal) electromyographic (EMG) activities due to perturbations of the intrathoracic trachea. SCH 225288 (0.03–3.0 mg/kg, i.v.) inhibited both cough number and abdominal EMG amplitudes. Similarly, SCH 225288 (0.001–0.3 mg/kg) administered intra-arterially also diminished cough number and abdominal EMG amplitudes. No significant effect of the drug was noted on parasternal EMG activity. Finally, we studied the antitussive actions of SCH 225288 (1.0 mg/kg) in a canine B. bronchiseptica disease model. In this model, dogs were challenged intranasally with B. bronchiseptica. Comparisons were made between a vehicle group, an SCH 225288 (1.0 mg/kg, p.o., q.d.) and a butorphanol (0.6 mg/kg, p.o., b.i.d.) group on the mean change in cough scores from baseline values and days 6–9 after B. bronchiseptica challenge. SCH 225288 (1.0 mg/kg, p.o., q.d.) displayed a positive antitussive tendency (p = 0.06) to inhibit B. bronchiseptica cough whereas butorphanol (0.6 mg/kg, p.o., b.i.d.) was devoid of antitussive activity. Conclusions: Taken together, the present data show that SCH 225288 is a potent and effective antitussive agent in animal models of cough. Furthermore, these findings indicate that NOP agonists represent a promising new therapeutic approach for the treatment of cough without the side effect liabilities associated with opioid antitussives.</description><identifier>ISSN: 0031-7012</identifier><identifier>EISSN: 1423-0313</identifier><identifier>DOI: 10.1159/000235601</identifier><identifier>PMID: 19696521</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Animals ; Antitussive Agents - administration & dosage ; Antitussive Agents - adverse effects ; Antitussive Agents - pharmacology ; Bordetella bronchiseptica - isolation & purification ; Bordetella Infections - drug therapy ; Bordetella Infections - veterinary ; Capsaicin ; Cats ; CHO Cells ; Cough - drug therapy ; Cricetinae ; Cricetulus ; Disease Models, Animal ; Dogs ; Dose-Response Relationship, Drug ; Female ; Guinea Pigs ; Humans ; Male ; Original Paper ; Receptors, Opioid - agonists ; Species Specificity ; Time Factors ; Tropanes - administration & dosage ; Tropanes - adverse effects ; Tropanes - pharmacology</subject><ispartof>Pharmacology, 2009-01, Vol.84 (3), p.153-161</ispartof><rights>2009 S. Karger AG, Basel</rights><rights>Copyright 2009 S. Karger AG, Basel.</rights><rights>Copyright (c) 2009 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-f43f222e4b2d0baabd84397ab0775c703b369ef5121dc73c861459dbacdc3ab03</citedby><cites>FETCH-LOGICAL-c361t-f43f222e4b2d0baabd84397ab0775c703b369ef5121dc73c861459dbacdc3ab03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19696521$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McLeod, Robbie L.</creatorcontrib><creatorcontrib>Tulshian, Deen B.</creatorcontrib><creatorcontrib>Ho, Ginny D.</creatorcontrib><creatorcontrib>Fernandez, Xiomara</creatorcontrib><creatorcontrib>Bolser, Donald C.</creatorcontrib><creatorcontrib>Parra, Leonard E.</creatorcontrib><creatorcontrib>Zimmer, Jennifer C.</creatorcontrib><creatorcontrib>Erickson, Christine H.</creatorcontrib><creatorcontrib>Fawzi, Ahmad B.</creatorcontrib><creatorcontrib>Jayappa, Huchappa</creatorcontrib><creatorcontrib>Lehr, Craig</creatorcontrib><creatorcontrib>Erskine, Jason</creatorcontrib><creatorcontrib>Smith-Torhan, April</creatorcontrib><creatorcontrib>Zhang, Hongtao</creatorcontrib><creatorcontrib>Hey, John A.</creatorcontrib><title>Effect of a Novel NOP Receptor Agonist (SCH 225288) on Guinea Pig Irritant-Evoked, Feline Mechanically Induced and Canine Infectious Tracheobronchitis Cough</title><title>Pharmacology</title><addtitle>Pharmacology</addtitle><description>Background: Previous studies have demonstrated that nociceptin/orphanin FQ (N/OFQ), the endogenous peptide ligand for the G-protein-coupled NOP receptor, inhibits cough in experimental models. SCH 225288 is a nonpeptide, orally active NOP agonist that may provide the foundation for the development of novel treatments for cough. Methods: First we characterized the selectivity of SCH 225288 in human receptor binding assays. Afterwards, the antitussive activity of SCH 225288 was studied in three mechanistically distinct cough models. Specifically, we observed the cough-suppressant effect of SCH 225288 in a guinea pig capsaicin irritant-evoked cough model, a feline mechanically induced cough model and finally in a canine Bordetella bronchiseptica disease model. Results: SCH 225288 selectively binds human NOP receptor (K i = 0.38 ± 0.02 nmol/l) over classical opioid receptors (COR). In a guinea pig capsaicin cough model, SCH 225288 (0.1–1 mg/kg) suppressed cough at 2, 4, and 6 h after oral administration. The antitussive effect of SCH 225288 (3.0 mg/kg, p.o.) was blocked by the NOP antagonist J113397 (12 mg/kg, i.p.) but not by the classical opioid receptor (COR) antagonist, naltrexone (3.0 mg/kg, i.p.). In the anesthetized cat, we evaluated the effects of SCH 225288 given either intravenously or via the intravertebral artery against the increases in cough number and respiratory expiratory and inspiratory muscle (rectus abdominis and parasternal) electromyographic (EMG) activities due to perturbations of the intrathoracic trachea. SCH 225288 (0.03–3.0 mg/kg, i.v.) inhibited both cough number and abdominal EMG amplitudes. Similarly, SCH 225288 (0.001–0.3 mg/kg) administered intra-arterially also diminished cough number and abdominal EMG amplitudes. No significant effect of the drug was noted on parasternal EMG activity. Finally, we studied the antitussive actions of SCH 225288 (1.0 mg/kg) in a canine B. bronchiseptica disease model. In this model, dogs were challenged intranasally with B. bronchiseptica. Comparisons were made between a vehicle group, an SCH 225288 (1.0 mg/kg, p.o., q.d.) and a butorphanol (0.6 mg/kg, p.o., b.i.d.) group on the mean change in cough scores from baseline values and days 6–9 after B. bronchiseptica challenge. SCH 225288 (1.0 mg/kg, p.o., q.d.) displayed a positive antitussive tendency (p = 0.06) to inhibit B. bronchiseptica cough whereas butorphanol (0.6 mg/kg, p.o., b.i.d.) was devoid of antitussive activity. Conclusions: Taken together, the present data show that SCH 225288 is a potent and effective antitussive agent in animal models of cough. Furthermore, these findings indicate that NOP agonists represent a promising new therapeutic approach for the treatment of cough without the side effect liabilities associated with opioid antitussives.</description><subject>Animals</subject><subject>Antitussive Agents - administration & dosage</subject><subject>Antitussive Agents - adverse effects</subject><subject>Antitussive Agents - pharmacology</subject><subject>Bordetella bronchiseptica - isolation & purification</subject><subject>Bordetella Infections - drug therapy</subject><subject>Bordetella Infections - veterinary</subject><subject>Capsaicin</subject><subject>Cats</subject><subject>CHO Cells</subject><subject>Cough - drug therapy</subject><subject>Cricetinae</subject><subject>Cricetulus</subject><subject>Disease Models, Animal</subject><subject>Dogs</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Guinea Pigs</subject><subject>Humans</subject><subject>Male</subject><subject>Original Paper</subject><subject>Receptors, Opioid - agonists</subject><subject>Species Specificity</subject><subject>Time Factors</subject><subject>Tropanes - administration & dosage</subject><subject>Tropanes - adverse effects</subject><subject>Tropanes - pharmacology</subject><issn>0031-7012</issn><issn>1423-0313</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpt0ctO3DAUBmCroioD7YI9QkfqpkiE-pLEyXIUDcxIXEYtXUeOLzOGYA92gsS78LAYzQg2XR3J59P_Sz4IHRF8TkhR_8YYU1aUmHxBE5JTlmFG2B6a4DQzjgndRwcx3idWUl59Q_ukLuuyoGSCXmfGaDmANyDgxj_rHm5ul_BHS70ZfIDpyjsbB_j1t5kDpQWtqlPwDi5H67SApV3BIgQ7CDdks2f_oNUZXOg-LeFay7VwVoq-f4GFU6PUCoRT0KTXtF-492brxwh3Qci19l3wTq7tYCM0flytv6OvRvRR_9jNQ_TvYnbXzLOr28tFM73KJCvJkJmcGUqpzjuqcCdEp6qc1Vx0mPNCcsw6VtbaFIQSJTmTVUnyoladkEqypNgh-rnN3QT_NOo4tPd-DC5VtgSXNeM5r_OkTrdKBh9j0KbdBPsowktC7fsd2o87JHuySxy7R60-5e7jPysfRFjp8AGW8-k2ot0ok9Txf9Wu5Q1x75YQ</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>McLeod, Robbie L.</creator><creator>Tulshian, Deen B.</creator><creator>Ho, Ginny D.</creator><creator>Fernandez, Xiomara</creator><creator>Bolser, Donald C.</creator><creator>Parra, Leonard E.</creator><creator>Zimmer, Jennifer C.</creator><creator>Erickson, Christine H.</creator><creator>Fawzi, Ahmad B.</creator><creator>Jayappa, Huchappa</creator><creator>Lehr, Craig</creator><creator>Erskine, Jason</creator><creator>Smith-Torhan, April</creator><creator>Zhang, Hongtao</creator><creator>Hey, John A.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20090101</creationdate><title>Effect of a Novel NOP Receptor Agonist (SCH 225288) on Guinea Pig Irritant-Evoked, Feline Mechanically Induced and Canine Infectious Tracheobronchitis Cough</title><author>McLeod, Robbie L. ; Tulshian, Deen B. ; Ho, Ginny D. ; Fernandez, Xiomara ; Bolser, Donald C. ; Parra, Leonard E. ; Zimmer, Jennifer C. ; Erickson, Christine H. ; Fawzi, Ahmad B. ; Jayappa, Huchappa ; Lehr, Craig ; Erskine, Jason ; Smith-Torhan, April ; Zhang, Hongtao ; Hey, John A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-f43f222e4b2d0baabd84397ab0775c703b369ef5121dc73c861459dbacdc3ab03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Antitussive Agents - administration & dosage</topic><topic>Antitussive Agents - adverse effects</topic><topic>Antitussive Agents - pharmacology</topic><topic>Bordetella bronchiseptica - isolation & purification</topic><topic>Bordetella Infections - drug therapy</topic><topic>Bordetella Infections - veterinary</topic><topic>Capsaicin</topic><topic>Cats</topic><topic>CHO Cells</topic><topic>Cough - drug therapy</topic><topic>Cricetinae</topic><topic>Cricetulus</topic><topic>Disease Models, Animal</topic><topic>Dogs</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Guinea Pigs</topic><topic>Humans</topic><topic>Male</topic><topic>Original Paper</topic><topic>Receptors, Opioid - agonists</topic><topic>Species Specificity</topic><topic>Time Factors</topic><topic>Tropanes - administration & dosage</topic><topic>Tropanes - adverse effects</topic><topic>Tropanes - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McLeod, Robbie L.</creatorcontrib><creatorcontrib>Tulshian, Deen B.</creatorcontrib><creatorcontrib>Ho, Ginny D.</creatorcontrib><creatorcontrib>Fernandez, Xiomara</creatorcontrib><creatorcontrib>Bolser, Donald C.</creatorcontrib><creatorcontrib>Parra, Leonard E.</creatorcontrib><creatorcontrib>Zimmer, Jennifer C.</creatorcontrib><creatorcontrib>Erickson, Christine H.</creatorcontrib><creatorcontrib>Fawzi, Ahmad B.</creatorcontrib><creatorcontrib>Jayappa, Huchappa</creatorcontrib><creatorcontrib>Lehr, Craig</creatorcontrib><creatorcontrib>Erskine, Jason</creatorcontrib><creatorcontrib>Smith-Torhan, April</creatorcontrib><creatorcontrib>Zhang, Hongtao</creatorcontrib><creatorcontrib>Hey, John A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McLeod, Robbie L.</au><au>Tulshian, Deen B.</au><au>Ho, Ginny D.</au><au>Fernandez, Xiomara</au><au>Bolser, Donald C.</au><au>Parra, Leonard E.</au><au>Zimmer, Jennifer C.</au><au>Erickson, Christine H.</au><au>Fawzi, Ahmad B.</au><au>Jayappa, Huchappa</au><au>Lehr, Craig</au><au>Erskine, Jason</au><au>Smith-Torhan, April</au><au>Zhang, Hongtao</au><au>Hey, John A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of a Novel NOP Receptor Agonist (SCH 225288) on Guinea Pig Irritant-Evoked, Feline Mechanically Induced and Canine Infectious Tracheobronchitis Cough</atitle><jtitle>Pharmacology</jtitle><addtitle>Pharmacology</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>84</volume><issue>3</issue><spage>153</spage><epage>161</epage><pages>153-161</pages><issn>0031-7012</issn><eissn>1423-0313</eissn><abstract>Background: Previous studies have demonstrated that nociceptin/orphanin FQ (N/OFQ), the endogenous peptide ligand for the G-protein-coupled NOP receptor, inhibits cough in experimental models. SCH 225288 is a nonpeptide, orally active NOP agonist that may provide the foundation for the development of novel treatments for cough. Methods: First we characterized the selectivity of SCH 225288 in human receptor binding assays. Afterwards, the antitussive activity of SCH 225288 was studied in three mechanistically distinct cough models. Specifically, we observed the cough-suppressant effect of SCH 225288 in a guinea pig capsaicin irritant-evoked cough model, a feline mechanically induced cough model and finally in a canine Bordetella bronchiseptica disease model. Results: SCH 225288 selectively binds human NOP receptor (K i = 0.38 ± 0.02 nmol/l) over classical opioid receptors (COR). In a guinea pig capsaicin cough model, SCH 225288 (0.1–1 mg/kg) suppressed cough at 2, 4, and 6 h after oral administration. The antitussive effect of SCH 225288 (3.0 mg/kg, p.o.) was blocked by the NOP antagonist J113397 (12 mg/kg, i.p.) but not by the classical opioid receptor (COR) antagonist, naltrexone (3.0 mg/kg, i.p.). In the anesthetized cat, we evaluated the effects of SCH 225288 given either intravenously or via the intravertebral artery against the increases in cough number and respiratory expiratory and inspiratory muscle (rectus abdominis and parasternal) electromyographic (EMG) activities due to perturbations of the intrathoracic trachea. SCH 225288 (0.03–3.0 mg/kg, i.v.) inhibited both cough number and abdominal EMG amplitudes. Similarly, SCH 225288 (0.001–0.3 mg/kg) administered intra-arterially also diminished cough number and abdominal EMG amplitudes. No significant effect of the drug was noted on parasternal EMG activity. Finally, we studied the antitussive actions of SCH 225288 (1.0 mg/kg) in a canine B. bronchiseptica disease model. In this model, dogs were challenged intranasally with B. bronchiseptica. Comparisons were made between a vehicle group, an SCH 225288 (1.0 mg/kg, p.o., q.d.) and a butorphanol (0.6 mg/kg, p.o., b.i.d.) group on the mean change in cough scores from baseline values and days 6–9 after B. bronchiseptica challenge. SCH 225288 (1.0 mg/kg, p.o., q.d.) displayed a positive antitussive tendency (p = 0.06) to inhibit B. bronchiseptica cough whereas butorphanol (0.6 mg/kg, p.o., b.i.d.) was devoid of antitussive activity. Conclusions: Taken together, the present data show that SCH 225288 is a potent and effective antitussive agent in animal models of cough. Furthermore, these findings indicate that NOP agonists represent a promising new therapeutic approach for the treatment of cough without the side effect liabilities associated with opioid antitussives.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>19696521</pmid><doi>10.1159/000235601</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0031-7012 |
ispartof | Pharmacology, 2009-01, Vol.84 (3), p.153-161 |
issn | 0031-7012 1423-0313 |
language | eng |
recordid | cdi_crossref_primary_10_1159_000235601 |
source | Karger Journals; MEDLINE; Alma/SFX Local Collection |
subjects | Animals Antitussive Agents - administration & dosage Antitussive Agents - adverse effects Antitussive Agents - pharmacology Bordetella bronchiseptica - isolation & purification Bordetella Infections - drug therapy Bordetella Infections - veterinary Capsaicin Cats CHO Cells Cough - drug therapy Cricetinae Cricetulus Disease Models, Animal Dogs Dose-Response Relationship, Drug Female Guinea Pigs Humans Male Original Paper Receptors, Opioid - agonists Species Specificity Time Factors Tropanes - administration & dosage Tropanes - adverse effects Tropanes - pharmacology |
title | Effect of a Novel NOP Receptor Agonist (SCH 225288) on Guinea Pig Irritant-Evoked, Feline Mechanically Induced and Canine Infectious Tracheobronchitis Cough |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T04%3A44%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20a%20Novel%20NOP%20Receptor%20Agonist%20(SCH%20225288)%20on%20Guinea%20Pig%20Irritant-Evoked,%20Feline%20Mechanically%20Induced%20and%20Canine%20Infectious%20Tracheobronchitis%20Cough&rft.jtitle=Pharmacology&rft.au=McLeod,%20Robbie%20L.&rft.date=2009-01-01&rft.volume=84&rft.issue=3&rft.spage=153&rft.epage=161&rft.pages=153-161&rft.issn=0031-7012&rft.eissn=1423-0313&rft_id=info:doi/10.1159/000235601&rft_dat=%3Cproquest_cross%3E2770126921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1069374794&rft_id=info:pmid/19696521&rfr_iscdi=true |